AS-Patisiran sodium（Cat No.:I041219）is an investigational RNA interference (RNAi) therapeutic designed to target and silence the gene responsible for producing transthyretin (TTR) proteins. By reducing the production of abnormal or wild-type TTR, AS-Patisiran sodium aims to treat transthyretin-mediated amyloidosis, a rare and progressive disease caused by the accumulation of TTR amyloid fibrils in various tissues, leading to organ damage. This compound is being explored for its potential to address both hereditary and wild-type forms of the disease, with ongoing clinical trials evaluating its safety, efficacy, and long-term benefits in affected patients.
